Screener
Vera Therapeutics VERA Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Vera Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:33 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212143
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest income | 6,355 | 6,906 |
| Interest expense | (1,823) | (1,792) |
| Other (expense) income, net | (432) | 386 |
| Total other income, net | 4,100 | 5,500 |
| Net loss | $(121,032) | $(51,694) |
| Other comprehensive income: | ||
| Change in unrealized gains and losses on marketable securities | (942) | 261 |
| Comprehensive loss | $(121,974) | $(51,433) |
Item 1. Financial Statements
FAQ
- What is Vera Therapeutics's other income (expense)?
- Vera Therapeutics (VERA) reported other income (expense) of $4.1M in Q1 2026.
- How has Vera Therapeutics's other income (expense) changed year-over-year?
- Vera Therapeutics's other income (expense) decreased by 25.5% year-over-year, from $5.5M to $4.1M.
- What is the long-term trend for Vera Therapeutics's other income (expense)?
- Over 3 years (2022 to 2025), Vera Therapeutics's other income (expense) has grown at a 104.7% compound annual growth rate (CAGR), from $1.85M to $15.86M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Vera Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude